NCT07872644Not yet recruiting
Safety in Ovarian Cancer for Average-Risk Women - Analysis
SOARA: Safety in Ovarian Cancer for Average-Risk Women - Analysis Clinical Validation Protocol
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1750 (estimated)
- First submitted
- 7 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- May 2028
- Lead sponsor
- Mercy BioAnalytics, Inc.
- Diseases
- Ovarian cancer
- NCT number
- NCT07872644
What you commit to
- Study type: Interventional
- Planned participants: 1750
- From Nov 2026 to the primary completion date, May 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving adjuvant chemotherapy or radiation therapy for cancer. Patients who are being treated may enroll 3 months after completion of last treatment.
Other illness
- Known genetic risk factors associated with ovarian cancer or hereditary cancer syndrome
- Currently under clinical surveillance due to a known or suspected elevated risk of developing ovarian cancer
- Women who are symptomatic and being evaluated for ovarian cancer
- Current untreated malignancy (other than non-melanoma skin cancer)
- Known conditions posing unacceptable phlebotomy risk (self-reported)
Other
- Removal of both ovaries for any reason
- Pregnant or breastfeeding
- Anticoagulant use (self-reported)
- Unwilling to provide the name of primary care physician or provider
- Unwilling to sign informed consent and/or medical records release form.
Who the study is looking for
- Postmenopausal women with one or both ovaries
- Age 50 years or more
- No personal history of ovarian cancer
- No hereditary cancer syndrome of genetic risk factors associated with ovarian cancer
- Willingness to allow medical record review
- Willingness to have blood drawn
- Ability to provide informed consent
Age in the registry: 50 years to - · Sex: Female · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 83Bar Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| Mercy BioAnalytics, Inc. Coordinator of this site? Confirm its status | Waltham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.